Herbal Formula Science (대한한의학방제학회지)

The Korean Medicine Society for the Herbal Formula Study (대한한의학방제학회)
권호 표지
DOI QR코드

DOI QR Code

Investigating herbal active ingredients and systems-level mechanisms on the human cancers

암치료를 위한 네트워크 기반 접근방식 활용 시스템 수준 연구

  • 이원융 (가천대학교 한의과대학)
  • Received : 2022.08.21
  • Accepted : 2022.08.26
  • Published : 2022.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : This study aims to investigate the active ingredients and potential mechanisms of the beneficial herb on human cancers such as the liver by employing network pharmacology. Methods : Ingredients and their target information was obtained from various databases such as TM-MC, TTD, and Drugbank. Related protein for liver cancer was retrieved from the Comparative Toxicogenomics Database and literature. A hypergeometric test and gene set enrichment analysis were conducted to evaluate associations between protein targets of red ginseng (Panax ginseng C. A. Meyer) and liver cancer-related proteins and identify related signaling pathways, respectively. Network proximity was employed to identify active ingredients of red ginseng on liver cancer. Results : A compound-target network of red ginseng was constructed, which consisted of 363 edges between 53 ingredients and 121 protein targets. MAPK signaling pathway, PI3K-Akt signaling pathway, p53 signaling pathway, TGF-beta signaling pathway, and cell cycle pathway was significantly associated with protein targets of red ginseng. Network proximity results indicated that Ginsenoside Rg1, Acetic Acid, Ginsenoside Rh2, 20(R)-Ginsenoside Rg3, Notoginsenoside R1, Ginsenoside Rk1, 2-Methylfuran, Hexanal, Ginsenoside Rd, Ginsenoside Rh1 could be active ingredients of red ginseng against liver cancer. Conclusion : This study suggests that network-based approaches could be useful to explore potential mechanisms and active ingredients of red ginseng for liver cancer.

Keywords

Acknowledgement

이 성과는 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구임 (NRF-2022R1I1A1A01057053).

References

  1. Shirakami Y, Sakai H, Shimizu M. Retinoid roles in blocking hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2015;4(4):1-7.
  2. Mancuso A, Perricone G. Hepatocellular carcinoma and liver transplantation: state of the art. J Clin Transl Hepatol. 2014;2(3):176-181.
  3. Nam KY, Lee NR, Moon BD, Song GY, Shin HS, Choi JE. Changes of ginsenosides and color from black ginsengs prepared by steaming-drying cycles. Korean J Med Crop Sci. 2012;20(1):27-35. https://doi.org/10.7783/KJMCS.2012.20.1.027
  4. Oh J, Jeon S Bin, Lee Y, Lee H, Kim J, Kwon BR, et al. Fermented red ginseng extract inhibits cancer cell proliferation and viability. J Med Food. 2015;18(4):421-428. https://doi.org/10.1089/jmf.2014.3248
  5. Zhu GY, Li YW, Tse AKW, Hau DKP, Leung CH, Yu ZL, et al. 20 (S)-Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells. Eur J Pharmacol. 2011;668(1):88-98. https://doi.org/10.1016/j.ejphar.2011.06.008
  6. Tian S, Huang P, Gu Y, Yang J, Wu R, Zhao J, et al. Systems Biology Analysis of the Effect and Mechanism of Qi-Jing-Sheng-Bai Granule on Leucopenia in Mice. 2019;10:1-16.
  7. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90. https://doi.org/10.1038/nchembio.118
  8. Lee WY, Lee CY, Kim YS, Kim CE. The methodological trends of traditional herbal medicine employing network pharmacology. Biomolecules. 2019;9(8):1-15.
  9. Guney E, Menche J, Vidal M, Barabasi AL. Network-based in silico drug efficacy screening. Nat Commun. 2016;7:1-13.
  10. Lee WY, Lee CY, Lee JS, Kim CE. Identifying candidate flavonoids for non-alcoholic fatty liver disease by network-based strategy. Front Pharmacol. 2022;13(892559):1-14.
  11. Kim SK, Nam SJ, Jang H, Kim A, Lee JJ. TM-MC: A database of medicinal materials and chemical compounds in Northeast Asian traditional medicine. BMC Complement Altern Med. 2015;15(218):1-8. https://doi.org/10.1186/s12906-015-0520-z
  12. Huang Y, Fang J, Lu W, Wang Z, Wang Q, Hou Y, et al. A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. Cell Chem Biol. 2019;26:1143-1158.e6. https://doi.org/10.1016/j.chembiol.2019.05.004
  13. Szklarczyk D, Santos A, Von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44:D380-D384. https://doi.org/10.1093/nar/gkv1277
  14. Zhu F, Han BC, Kumar P, Liu XH, Ma XH, Wei XN, et al. Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2009;38:D787-791.
  15. Koopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw T, Coba MP, et al. SynGO: an evidence-based, expert-curated knowledge base for the synapse. Neuron. 2019;103(2):217-234. https://doi.org/10.1016/j.neuron.2019.05.002
  16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504. https://doi.org/10.1101/gr.1239303
  17. Davis AP, Grondin CJ, Johnson RJ, Sciaky D, McMorran R, Wiegers J, et al. The Comparative Toxicogenomics Database: Update 2019. Nucleic Acids Res. 2019;47:D948-D954 https://doi.org/10.1093/nar/gky868
  18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. https://doi.org/10.1073/pnas.0506580102
  19. Gene Ontology Consortium. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32:D258-D261 https://doi.org/10.1093/nar/gkh036
  20. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999;27(1):29-34. https://doi.org/10.1093/nar/27.1.29
  21. Gao Y, Chu S, Zhang Z, Chen N. Hepataprotective effects of ginsenoside Rg1-A review. J Ethnopharmacol. 2017;206:178-183. https://doi.org/10.1016/j.jep.2017.04.012
  22. Yang Z, Zhao T, Liu H, Zhang L. Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep.2016;6(19383):1-13. https://doi.org/10.1038/s41598-016-0001-8
  23. Li Y, Li Z, Jia Y, Ding B, Yu J. In vitro anti-hepatoma activities of notoginsenoside R1 through downregulation of tumor promoter miR-21. Digestive diseases and sciences, 2020;65(5):1364-1375. https://doi.org/10.1007/s10620-019-05856-4
  24. Kim YJ, Kwon HC, Ko H, Park JH, Kim HY, Yoo JH, Yang HO. Anti-tumor activity of the ginsenoside Rk1 in human hepatocellular carcinoma cells through inhibition of telomerase activity and induction of apoptosis. Biological and Pharmaceutical Bulletin, 2008;31(5):826-830. https://doi.org/10.1248/bpb.31.826